HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy.

By FierceBiotech · Apr 21, 2026 · via FierceBiotech
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Lilly Spends Up to $3.8B on Three Vaccine Developers
DealsBriefing
Lilly Spends Up to $3.8B on Three Vaccine Developers
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
May 26, 2026
Medtronic inks $650M deal for SPR Therapeutics
DealsFierceBiotech ↗
Medtronic inks $650M deal for SPR Therapeutics
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
May 24, 2026
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
DealsPharmaceutical Technology ↗
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
May 22, 2026